|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0331858,
umls-concept:C0441655,
umls-concept:C0442027,
umls-concept:C0723595,
umls-concept:C0796679,
umls-concept:C1152589,
umls-concept:C1412186,
umls-concept:C1555721,
umls-concept:C1704640,
umls-concept:C1706204,
umls-concept:C1706515,
umls-concept:C2936235
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
2001-8-21
|
|
pubmed:abstractText |
N-Hydroxyformamide-class metalloprotease inhibitors were designed and synthesized, which have potent broad-spectrum activity versus matrix metalloproteases and TNF-alpha converting enzyme (TACE). Compound 13c possesses good oral and intravenous pharmacokinetics in the rat and dog.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:AndersenM WMW,
pubmed-author:AndrewsR CRC,
pubmed-author:AustinRR,
pubmed-author:BeaudetE JEJ,
pubmed-author:BechererJ DJD,
pubmed-author:BickettD MDM,
pubmed-author:BubaczD GDG,
pubmed-author:ChanJ HJH,
pubmed-author:ConwayJ GJG,
pubmed-author:CowanD JDJ,
pubmed-author:GaulM DMD,
pubmed-author:GlennonK CKC,
pubmed-author:HedeenK MKM,
pubmed-author:LambertM HMH,
pubmed-author:LeesnitzerM AMA,
pubmed-author:McDougaldD LDL,
pubmed-author:MitchellJ LJL,
pubmed-author:MossM LML,
pubmed-author:MussoD LDL,
pubmed-author:RabinowitzM HMH,
pubmed-author:RizzolioM CMC,
pubmed-author:SchallerL TLT,
pubmed-author:StanfordJ BJB,
pubmed-author:TippinTT,
pubmed-author:WarnerJ RJR,
pubmed-author:WhitesellL GLG,
pubmed-author:WietheR WRW
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2147-51
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.
|
|
pubmed:affiliation |
GlaxoSmithKline Research and Development, Five Moore Drive, Research Triangle Park, NC 27709, USA. dm12907@glaxowellcome.com
|
|
pubmed:publicationType |
Journal Article
|
